K Number
K251770

Validate with FDA (Live)

Manufacturer
Date Cleared
2025-12-15

(188 days)

Product Code
Regulation Number
868.5905
Age Range
All
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticPediatricDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The SleepRes PAP system is indicated for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. (30 kg.). The SleepRes PAP system is intended for home, hospital / institutional and sleep center settings.

Device Description

The SleepRes PAP system consists of a firmware-controlled console, power cable and power adapter, air filter, water tank, and heated breathing tube. The PAP console is composed of a control system, motor system, and heating system. The control system includes the main board, buttons, screen, and sensor. The motor system includes the motor, fan blade, motor outer shell, and silence box. The heating system includes a heating plate and temperature sensor. The PAP console of the subject device does not include foam.

The SleepRes PAP system also includes the following components of PAP therapy systems:

  • Water tank
  • Air filter
  • Breathing Tube

The SleepRes PAP system offers several modes:

  • CPAP
    • Provides continuous positive airway pressure at the prescribed pressure
  • APAP
    • Functions to titrate the pressure up (and down as well) to balance reducing or eliminating sleep events while using the lowest effective pressure. Pressure limits are pre-set by the prescribing clinician.
  • Kairos Positive Airway Pressure (KPAP)
    • This algorithm reduces airway pressure during both inspiration and during most of expiration, only returning pressure to the prescribed treatment level towards the end of expiration.

Connectivity to a Cloud platform via Wi-Fi connection.

AI/ML Overview

The provided FDA 510(k) clearance letter and summary for the SleepRes PAP System (K251770) offer some details about acceptance criteria and the study that proves the device meets these criteria. However, it's important to note that a 510(k) summary is a high-level overview and does not typically contain all the granular details of a full study report.

Here's an attempt to extract and present the requested information based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The 510(k) summary broadly asserts that the device met performance and safety requirements. Specific, quantifiable acceptance criteria with corresponding performance outcomes are not explicitly listed in a detailed format within the provided document, beyond the comparison table with the predicate.

Acceptance Criteria (Inferred from Predicate Comparison & Testing)Reported Device Performance (SleepRes PAP System)
Pressure Range4 to 20 cmH2O
Pressure Accuracy (Static)+/- 0.5 cmH2O
Pressure Accuracy (Dynamic)+/- 1.0 -1.5 cmH2O from 10-20 BPM
Flow Range10-60 lpm
Flow Accuracy+/- 2 lpm or 10% of reading
Operating Temperature Range5℃ to 32℃ (41˚F to 95˚F)
Storage Temperature Range-20℃ to 55℃ (-13˚F to 158˚F)
Atmospheric Pressure Range700 to 1060 hPa (0-3000m / 0-9880ft)
Noise / Sound<35 dB(A) (Note: Higher than predicate's 27 dB(A), addressed by labeling mitigation)
Therapy Algorithm Effectiveness (Comparative Sleep Studies)Substantially equivalent to predicate in disordered breathing events (AHI3a), sleep quality, and sleep architecture.
BiocompatibilityMet ISO 10993 and ISO 18562 series requirements, including post-accelerated aging tests.
Electrical Safety and EMCComplied with IEC 60601-1 and related collateral standards.
Software Verification and ValidationConducted as per FDA guidances.
Human Factors ValidationConducted as per FDA guidances.

2. Sample Size Used for the Test Set and Data Provenance

  • Sample Size for Test Set: 50 OSA patients.
  • Data Provenance: The document states "Each patient underwent a full night polysomnogram." It does not specify the country of origin of the data. The study involved patients "all of whom were on standard APAP in the home," implying they were existing patients.
  • Retrospective or Prospective: Implied to be prospective for the clinical validation part, as it describes a protocol where patients "underwent a full night polysomnogram" with different treatment conditions (CPAP, APAP, and APAP + KPAP) specifically for the study.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

The document does not specify the number or qualifications of experts used to establish the ground truth for the test set (polysomnogram scoring). It only mentions "PSG sleep studies."

4. Adjudication Method for the Test Set

The document does not specify the adjudication method for the test set (PSG scoring).

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

  • Was an MRMC study done? No, an MRMC study was not explicitly described. The clinical study focused on patient outcomes comparing devices/algorithms, not on human readers' performance with or without AI assistance.
  • Effect size of human readers improvement: Not applicable, as this was not an MRMC study assessing human reader performance. The study compared the device's therapy algorithms directly through patient outcomes.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done

While the clinical study evaluated the device's algorithms (APAP and KPAP) directly through patient polysomnography, it's not described as a "standalone algorithm-only" performance evaluation in the context of interpretation often seen in AI/ML applications. Rather, it evaluated the therapy delivered by the device to patients. The outcomes (AHI3a, sleep quality, sleep architecture) are direct measures of the device's therapeutic effect.

7. The Type of Ground Truth Used

  • Type of Ground Truth: Polysomnography (PSG) results, specifically metrics like AHI3a (Apnea-Hypopnea Index with 3% desaturation or arousal criterion), sleep quality, and measures of sleep architecture. These are clinical outcomes obtained from detailed sleep studies.

8. The Sample Size for the Training Set

The document does not specify the sample size for the training set. It only describes the clinical validation study's test set.

9. How the Ground Truth for the Training Set Was Established

Since no training set details are provided, the method for establishing its ground truth is not mentioned.

FDA 510(k) Clearance Letter - SleepRes PAP System

Page 1

December 15, 2025

SleepRes, Inc
℅ Paul Dryden
Consultant
ProMedic, LLC
131 Bay Point Dr NE
St. Petersburg, Florida 33704

Re: K251770
Trade/Device Name: SleepRes PAP System
Regulation Number: 21 CFR 868.5905
Regulation Name: Noncontinuous Ventilator (IPPB)
Regulatory Class: Class II
Product Code: BZD, BZE
Dated: November 16, 2025
Received: November 17, 2025

Dear Paul Dryden:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of

Page 2

K251770 - Paul Dryden
Page 2

Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn

Page 3

K251770 - Paul Dryden
Page 3

(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Binoy J. Mathews -S
Digitally signed by Binoy J. Mathews -S
Date: 2025.12.15 17:08:05 -05'00'

For

Rachana Visaria
Assistant Director
DHT1C: Division of Anesthesia, Respiratory, and Sleep Devices
OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Page 4

FORM FDA 3881 (6/20)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EF

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.

510(k) Number (if known): K251770

Device Name: SleepRes PAP system

Indications for Use (Describe)

The SleepRes PAP system is indicated for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. (30 kg.). The SleepRes PAP system is intended for home, hospital / institutional and sleep center settings.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.


This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Page 5

K251770 510(k) Summary

Page 1 of 9

Date Prepared: December 15, 2025

Sponsor: SleepRes, Inc.
1508 Carl Adams Dr Ste 200
Murfreesboro, TN 37129
Tel: (615) 921-2406

Sponsor Contact: Craig Salazar - Chief Financial Officer

Submission Correspondent: Paul Dryden
ProMedic, LLC

Proprietary or Trade Name: SleepRes PAP system
Common/Usual Name: CPAP
Classification Name: BZD – 868.5905 - Noncontinuous Ventilator (IPPB)
Secondary: BZE – 868.5270 - Breathing System Heater

Predicate Device: Philips DreamStation 2 - K200480
Common/Usual Name: CPAP
Classification Name: BZD – 868.5905 - Noncontinuous Ventilator (IPPB)

Reference Device: Exceleron Thermalite CPAP Heated Tubing - K241268
Common/Usual Name: Heated CPAP Hose
Classification Name: BZE – 868.5270 - Breathing System Heater

Device Description

The SleepRes PAP system consists of a firmware-controlled console, power cable and power adapter, air filter, water tank, and heated breathing tube. The PAP console is composed of a control system, motor system, and heating system. The control system includes the main board, buttons, screen, and sensor. The motor system includes the motor, fan blade, motor outer shell, and silence box. The heating system includes a heating plate and temperature sensor. The PAP console of the subject device does not include foam.

The SleepRes PAP system also includes the following components of PAP therapy systems:

  • Water tank
  • Air filter
  • Breathing Tube

The SleepRes PAP system offers several modes:

  • CPAP
    • Provides continuous positive airway pressure at the prescribed pressure
  • APAP
    • Functions to titrate the pressure up (and down as well) to balance reducing or eliminating sleep events while using the lowest effective pressure. Pressure limits are pre-set by the prescribing clinician.
  • Kairos Positive Airway Pressure (KPAP)
    • This algorithm reduces airway pressure during both inspiration and during most of expiration, only returning pressure to the prescribed treatment level towards the end of expiration.

Connectivity to a Cloud platform via Wi-Fi connection.

Page 6

K251770
510(k) Summary
Page 2 of 9

Principle of Operation

A PAP therapy system works by creating and delivering pressurized air into the airway through a patient interface, mask or nasal pillows, to keep the airway open while sleeping. The pressure is set to a therapy level, or it can change based on the patient's breathing needs. Typical therapy pressure averages 11-12 cmH2O but can range from between 4 and 20 cmH2O during APAP use.

Indications for Use:

The SleepRes PAP system is indicated for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. (30 kg.). The SleepRes PAP system is intended for home, hospital / institutional and sleep center settings.

Page 7

510(k) Summary
Page 3 of 9

Table 1 - Comparison of Subject vs. Predicate

Subject device SleepRes PAP System K251770Predicate Philips DreamStation 2 K200480Comparison
Product CodeBZD – 868.5905 Noncontinuous Ventilator (IPPB) BZE – 868.5270 Breathing System HeaterBZD – 868.5905 Noncontinuous Ventilator (IPPB)Similar
Indications for UseThe SleepRes PAP system is intended to deliver positive airway pressure therapy for the treatment of obstructive sleep apnea (OSA) in patients weighing over 30 kg. (66 lbs.). The SleepRes PAP system is intended for home, hospital / institutional and sleep center settings.The DreamStation 2 CPAP / DreamStation 2 Auto CPAP system delivers positive airway pressure therapy for the treatment of Obstructive Sleep Apnea in spontaneously breathing patients weighing over 30 kg (66 lbs). It is for use in the home or hospital/institutional environment.Similar to
Patient PopulationPatients weighing over 30 kg (66 lbs).Patients weighing over 30 kg (66 lbs).Similar to
Environment of UseHome, hospital/institutional and sleep center settingsHome, hospital/institutional environmentSimilar to
Fundamental scientific technologyMicroprocessor Software controlled Blower HeaterMicroprocessor Software controlled Blower HeaterSimilar to
Modes of OperationCPAP Auto CPAP (APAP) KPAPCPAP Auto CPAP - Auto-Trial - CPAP-check C-FlexBoth devices adjust pressure during inspiration and then increase pressure during expiration. Sleep comparison of algorithms demonstrated any difference does not raise different risks compared to predicate
Energy deliveredContinuous Positive Airway Pressure (CPAP)Continuous Positive Airway Pressure (CPAP)Similar to
Pressure Range4 to 20 cmH2O4 to 20 cmH2OSimilar to
Pressure Accuracy Static Dynamic+/- 0.5 cmH2O +/- 1.0 -1.5 cmH2O from 10-20 BPM+/- 0.5 cmH2O for 15 and 22mm tubing +/- 1.0 cmH2O for 12 mm tubing +/- 1.0 cmH2O for 15 and 22mm tubing +/- 2.0 cmH2O for 12 mm tubingSimilar to
Flow Range10-60 lpm10-60 lpmSimilar to

Page 8

K251770
510(k) Summary
Page 3 of 9

Table 1 - Comparison of Subject vs. Predicate (continued)

Subject device SleepRes PAP System K251770Predicate Philips DreamStation 2 K200480Comparison
Accuracy+/- 2 lpm or 10% of reading
HumidifierIntegratedIntegratedSimilar to
Water tank capacity250 ml325 mlSimilar to
Patient InterfaceUser supplied Mask Nasal pillowsMask Nasal pillowsSimilar to
CleaningMain unit – exterior only Water tank – soap and water Heated Tube – soap and waterMain unit – exterior only Water tank – soap and water Heated Tube – soap and waterSimilar to
Specifications Dimensions Weight243mm x 181mm x 110mm 1370 grams274mm x 158mm x 85mm 1040 gramsSimilar to
Operating temperature range5℃ to 32℃ (41˚F to 95˚F)5° to 35°C (41° to 95°F)Similar to
Storage Temperature range-20℃ to 55℃ (-13˚F to 158˚F)-20° to 60°C (-4° to 140°F)Similar to
Service LifeWater Tank – 6 months Heated Tubing – 3 monthsWater Tank – 12 months Heated Tubing – 6 monthsSimilar to
Atmospheric Pressure700 to 1060 hPa (0-3000m / 0-9880ft)101 to 77 kPa (0 - 2286m / 0 - 7500ft)Similar to
Electrical Safety and EMCInput: AC100-240V, 50/60Hz 1.8Amax Output: DC24V, 3.33AInput: AC100–240 VAC, 50/60 Hz 2.0-1.0 A Output: DC 12VSimilar to
Noise / Sound<35 dB(A)27 dB(A)higher than the predicate; Labeling mitigation added to address difference*
Therapy algorithm comparisonComparative Sleep studies were substantially equivalentComparative Sleep studies were substantially equivalentSimilar to
CommunicationsWi-FiWi-Fi BLE CellularSimilar to

*Warnings have been included on the user manual to inform the users about the device sound pressure level as compared to the recommended level by the World Health Organization.

Page 9

K251770
510(k) Summary
Page 4 of 9

Table 2 - Comparison of Heated Tubing Subject vs. Reference

Subject device SleepRes PAP System K251770Reference Exceleron Thermalite CPAP Heated Tubing K241268
Product CodeBZD – 868.5905 Noncontinuous Ventilator (IPPB) BZE – 868.5270 Breathing System HeaterBZE – 868.5270 Breathing System Heater
Indications for UseThe SleepRes PAP system is intended to deliver positive airway pressure therapy for the treatment of obstructive sleep apnea (OSA) in patients weighing over 30 kg. (66 lbs.). The SleepRes PAP system is intended for home, hospital / institutional and sleep center settings.The THERMALITE® CPAP Heated Tubing is a heated wire breathing tube intended to provide warmed and/or humidified breathing gases before they enter a patient's airway. It is indicated for single-patient reuse in the home and in clinical settings, such as hospitals, institutions, sleep laboratories, and sub-acute care facilities. It may be used with noninvasive ventilation for adult patients. It is compatible with the Philips Respironics DreamStation 1 and DreamStation 2 heated humidifiers
Patient PopulationPatients weighing over 30 kg (66 lbs).Adult patients
Environment of UseHome, hospital/institutional and sleep center settingsHome, hospital/institutional environment
Operating PrincipleDuring use a voltage is applied and a current flows through the heating wires.During use a voltage is applied and a current flows through the heating wires, encapsulated in the tubing.
TechnologyThe power is generated by the humidifier and due to the wire resistance in the device. Main unit controller monitors temperature and regulates the current through the heated wires and thereby regulates the temperature of the breathed air.The power is generated by the humidifier and due to the wire resistance in the device, heat is dissipated through the wall of the tube construction into the air flow in the lumen of the tubing. An in circuit integrated Negative Temperature Coefficient thermistor (NTC) at the mask-end senses the temperature of the passing air flow. The resistance characteristics of the NTC changes with temperature and regulates the current through the heated wires and thereby regulates the temperature of the breathed air.
DimensionsID – 22 mm Length – 1.83 mID – 22 mm Length – 1.83 m

Page 10

K251770
510(k) Summary
Page 5 of 9

Table 2 - Comparison of Heated Tubing Subject vs. Reference (continued)

Subject device SleepRes PAP System K251770Reference Exceleron Thermalite CPAP Heated Tubing K241268Comparison
Product CodeBZD – 868.5905 Noncontinuous Ventilator (IPPB) BZE – 868.5270 Breathing System HeaterSimilar
Indications for UseThe SleepRes PAP system is intended to deliver positive airway pressure therapy for the treatment of obstructive sleep apnea (OSA) in patients weighing over 30 kg. (66 lbs.). The SleepRes PAP system is intended for home, hospital / institutional and sleep center settings.The THERMALITE® CPAP Heated Tubing is a heated wire breathing tube intended to provide warmed and/or humidified breathing gases before they enter a patient's airway. It is indicated for single-patient reuse in the home and in clinical settings, such as hospitals, institutions, sleep laboratories, and sub-acute care facilities. It may be used with noninvasive ventilation for adult patients. It is compatible with the Philips Respironics DreamStation 1 and DreamStation 2 heated humidifiersSimilar
Patient PopulationPatients weighing over 30 kg (66 lbs).Adult patientsSimilar
Environment of UseHome, hospital/institutional and sleep center settingsHome, hospital/institutional environmentSimilar
Operating PrincipleDuring use a voltage is applied and a current flows through the heating wires.During use a voltage is applied and a current flows through the heating wires, encapsulated in the tubing.Similar
TechnologyThe power is generated by the humidifier and due to the wire resistance in the device. Main unit controller monitors temperature and regulates the current through the heated wires and thereby regulates the temperature of the breathed air.The power is generated by the humidifier and due to the wire resistance in the device, heat is dissipated through the wall of the tube construction into the air flow in the lumen of the tubing. An in circuit integrated Negative Temperature Coefficient thermistor (NTC) at the mask-end senses the temperature of the passing air flow. The resistance characteristics of the NTC changes with temperature and regulates the current through the heated wires and thereby regulates the temperature of the breathed air.Similar
DimensionsID – 22 mm Length – 1.83 mID – 22 mm Length – 1.83 mSimilar

Page 11

K251770
510(k) Summary
Page 6 of 9

Subject device SleepRes PAP SystemReference Exceleron Thermalite CPAP Heated Tubing K241268Comparison
ReusableSingle-patient, multi-use Clean – soap and waterSingle-patient, multi-use Clean – soap and waterSimilar
Power SourceHumidifier controllerHumidifier controllerSimilar

Page 12

K251770
510(k) Summary
Page 7 of 9

Discussion of Differences Between Subject and Predicates

We presented in the tables above a comparison of the proposed device and then the accessory. We have provided the rationale for the use of a predicate for the proposed PAP system. Separately, we compared the accessory heated wire hose to a reference device.

Technological Characteristics –

The subject device and the predicate, Philips DreamStation 2 utilize a blower to generate pressure and therefore flow to the patient which is software controlled. Each device has a series of algorithms which include APAP, CPAP and a feature referred to as KPAP and C-Flex for the subject device and predicate, respectively. The subject device and the predicate both include an integrated humidifier which provides heat and humidification to the patient via a heated wire hose. We compared the technology of the heated wire hose to a reference device, Exceleron Thermalite, which was found to be similar in all features and functions and is considered substantially equivalent. Both the subject device and the predicate include types of wireless connectivity which permits data transfer for review by the provider who may also provide changes to the PAP device.

Non-clinical Testing –

The proposed device has been tested to all applicable standards that include:

  • ISO 5367:2023 Anaesthetic and respiratory equipment — Breathing sets and connectors
  • IEC 60601-1: 2005 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
  • IEC 60601-1-2: 2020 Medical electrical equipment – Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility – Requirements and tests
  • IEC 60601-1-11: 2015 Medical electrical equipment – Part 1-11: General requirements for basic safety and essential performance — Collateral standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment
  • ISO 80601-2-70:2020 Medical electrical equipment – Part 2-70: Particular requirements for basic safety and essential performance of sleep apnoea breathing therapy equipment
  • ISO 80601-2-74:2021 Medical electrical equipment – Part 2-74: Particular requirements for basic safety and essential performance of respiratory humidifying equipment

Software verification and validation testing were conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff:

  • "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices"
  • "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices"

Human factors validation was conducted according to FDA's Guidance for Industry and FDA Staff:

  • "Applying Human Factors and Usability Engineering to Medical Devices"

Additional non-clinical performance testing included:

  • Storage
  • Transportation
  • Service-life
  • Altitude
  • Cleaning
  • Wireless coexistence
  • Comparative waveform Testing

Page 13

K251770
510(k) Summary
Page 8 of 9

Biocompatibility Assessment

The subject device is categorized as permanent contact duration (>30 days) including dry and humidified gas pathways. The following Biocompatibility testing was performed.

  • ISO 10993-1: 2025 Biological evaluation of medical devices Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process
  • ISO 10993-5:2009 Biological evaluation of medical devices – Part 5: Tests for in vitro cytotoxicity
  • ISO 10993-10:201 Biological evaluation of medical devices – Part 10: Tests for irritation and skin sensitization
  • ISO 10993-23, 2021, Biological Evaluation of Medical Devices - Part 23: Tests for Irritation
  • ISO 10993−11, 2017, Biological Evaluation of Medical Devices − Part 11: Tests for Systemic Toxicity -Acute Systemic Toxicity and Material Mediated Pyrogenicity
  • ISO/TR 10993-33, 2015, Biological Evaluation of Medical Devices - Part 33: Guidance on Tests to Evaluate Genotoxicity - Supplement to ISO 10993-3.
  • ISO 10993-18:2020 – Biological evaluation of medical devices – part 18: Chemical characterization of medical device materials within a risk management process and TRA
  • ISO 18562-1: 2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications Part 1: Evaluation and testing within a risk management process
  • ISO 18562-2:2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications – Part 2: Tests for emissions of particulate matter
  • ISO 18562-3:2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications – Part 3: Tests for emissions of volatile organic compounds (VOCs) and Inorganic gases – CO, CO2 and Ozone
  • ISO 18562-4: 2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications Part 4: Tests for leachables in condensate

Additionally, to verify the biocompatibility of the subject device at end of service-life following testing was conducted post accelerated aging.

  • ISO 18562-2:2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications – Part 2: Tests for emissions of particulate matter
  • ISO 18562-3:2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications – Part 3: Tests for emissions of volatile organic compounds (VOCs)

The proposed device demonstrated that it met the performance and safety requirements to be found safe and effective compared to the predicates.

Clinical Testing

A clinical validation study was conducted to support the substantial equivalence of the SleepRes APAP device, a Philips APAP device and the SleepRes APAP + KPAP algorithms. The proposed device was compared in PSG sleep studies to the primary predicate for the treatment of OSA.

This study consisted of 50 OSA patients all of whom were on standard APAP in the home. Each patient underwent a full night polysomnogram. Half of the night was spent on CPAP and the other half of the night on APAP, and APAP + KPAP.

The results demonstrated no significant difference in disordered breathing events (AHI3a), sleep quality and metrics of sleep architecture between treatments.

Substantial Equivalence Conclusion

The comparison of features and specifications, non-clinical performance testing and the comparative clinical studies demonstrate that the proposed device is substantially equivalent to the predicates.

Page 14

K251770
510(k) Summary
Page 9 of 9

Any differences do not raise different concerns of safety or effectiveness when compared to the predicates.

§ 868.5905 Noncontinuous ventilator (IPPB).

(a)
Identification. A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing.(b)
Classification. Class II (performance standards).